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Min Ren8, Corina E. Dutcus8, Fabio Piscaglia9 and Max W. Sung10
BACKGROUND: Proteinuria monitoring is required in patients receiving lenvatinib, however, current methodology involves
burdensome overnight urine collection.
METHODS: To determine whether the simpler urine protein:creatinine ratio (UPCR) calculated from spot urine samples could be
accurately used for proteinuria monitoring in patients receiving lenvatinib, we evaluated the correlation between UPCR and 24-
hour urine protein results from the phase 3 REFLECT study. Paired data (323 tests, 154 patients) were analysed.
RESULTS: Regression analysis showed a statistically significant correlation between UPCR and 24-hour urine protein (R2: 0.75; P <
2 × 10−16). A UPCR cut-off value of 2.4 had 96.9% sensitivity, 82.5% specificity for delineating between grade 2 and 3 proteinuria.
Using this UPCR cut-off value to determine the need for further testing could reduce the need for 24-hour urine collection in ~74%
of patients.
CONCLUSION: Incorporation of UPCR into the current algorithm for proteinuria management can enable optimisation of lenvatinib
treatment, while minimising patient inconvenience.
CLINICAL TRIAL REGISTRATION: NCT01761266
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BACKGROUND
Lenvatinib is a multikinase inhibitor of vascular endothelial growth
factor receptors (VEGFR) 1‒3, fibroblast growth factor receptors
1–4, platelet-derived growth factor-alpha, KIT, and RET.1,2 Lenva-
tinib monotherapy is indicated for first-line treatment of
unresectable hepatocellular carcinoma (HCC)3,4 based on results
from the phase 3 REFLECT study, where lenvatinib demonstrated a
treatment effect on overall survival with statistical confirmation of
noninferiority to sorafenib (13.6 vs 12.3 months, respectively;
hazard ratio 0.92; 95% confidence interval 0.79–1.06), along with
significant improvements in progression-free survival, time to
progression, and objective response rates.5 Lenvatinib is also
indicated as monotherapy for patients with locally recurrent or
metastatic, progressive, radioiodine-refractory differentiated thyr-
oid cancer (RR-DTC), and in combination with everolimus
in patients with advanced renal cell carcinoma (RCC) following
1 prior anti-angiogenic therapy.3
Proteinuria is a class effect of antiangiogenic agents,6 and a
well-documented lenvatinib-associated adverse effect.5,7–9 Rates
of any-grade/grade ≥3 proteinuria observed in lenvatinib-treated
patients were 25%/6% in the phase 3 REFLECT study in
unresectable HCC,5 31%/10% in the phase 3 SELECT in patients
with RR-DTC,8 and 31%/19% in a phase 2 study in patients with
advanced/metastatic RCC.7
Patients receiving lenvatinib are monitored regularly for
proteinuria using a urine sample dipstick method. The current
standard management requires a 24-hour urine protein test if a
dipstick proteinuria result of ≥2+ is detected, with the recom-
mendation that lenvatinib treatment should be withheld if a
proteinuria level of ≥2 g/24 h is detected.3 This 24-hour urine
protein test relies on patient collection of urine overnight, which is
burdensome and may be influenced by patient compliance.
However, the single (“spot”) urine protein:creatinine ratio (UPCR) is
a simple and convenient alternative test that is often used to
detect proteinuria associated with certain medical conditions, e.g.,
chronic kidney disease and diabetes.10,11 UPCR is calculated by
dividing the level of protein (mg/dl) in a spot urine test by the
creatinine level (mg/dl).12 This approach was first validated in 1983
by Ginsberg and colleagues.13 It is based on the premise that
urinary creatinine excretion and the protein excretion rate in the
presence of a stable glomerular filtration rate are fairly constant in
a given patient. Thus, a simple ratio of the 2 in a single-void urine
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sample would reflect cumulative protein excretion over a day
(because the ratio of 2 stable rates would cancel out the time
factor).
To determine whether UPCR could be a useful and more
convenient assessment for proteinuria in patients receiving
lenvatinib, we evaluated the correlation between proteinuria
assessment by UPCR and 24-hour urine protein in patients with
HCC from the REFLECT study.
MATERIALS AND METHODS
Study design and patients
Details of the REFLECT study have been published previously.5
Briefly, REFLECT was an international, randomised, open-label,
noninferiority study, which enroled 954 previously untreated
patients with unresectable HCC from 154 sites in 20 countries
throughout Asia-Pacific, European, and North American regions.
Patients were randomised (1:1) to receive lenvatinib (n= 478) or
sorafenib (n= 476).
End points and assessments
All patients underwent urine dipstick testing at each scheduled
safety assessment visit (day 1 and day 15 of the first 2 cycles, then
day 1 of each subsequent cycle). Within 72 h of a positive (≥2)
proteinuria urine dipstick test during regular safety assessment
visits, patients underwent standard-of-care 24-hour urine collec-
tion for total protein, performed either at the central or local site
laboratories, as well as a UPCR test, performed at the central
laboratory. 24-Hour urine collection was used to grade proteinuria
according to Common Terminology Criteria for Adverse Events
(CTCAE) v4.0 criteria (Supplementary Table 1). Patients with
positive urine dipstick test underwent dipstick testing every
2 weeks until results were reduced to 1+ or negative for 3
consecutive months.
Statistical analyses
Paired data were analysed. Optimal UPCR cut-off values were
identified using standard receiver operating characteristic meth-
ods to maximise the Youden index/statistics (sensitivity+
specificity), with urine data dichotomised by CTCAE proteinuria
grades (grade <2 vs ≥2 and grade ≤2 vs 3). The correlation
between 24-hour urine protein data (as continuous values) and
UPCR was analysed using a regression model of log-transformed
data. Also, the optimal UPCR cut-off value determining which
patients should undergo further testing with 24-hour urine
collection was calculated. Statistical analyses were performed
using R statistical software.
RESULTS
Paired data (323 paired tests) from 154 patients were included in
the analysis.
Cut-off values for UPCR
The optimal cut-off to discriminate grade 1 (1+ proteinuria;
urinary protein <1.0 g/24 h) from grade ≥2 (2+ proteinuria; urinary
protein >1.0 g/24 h) proteinuria by UPCR was 1.02, (94.0%
sensitivity; 72.4% specificity) (Supplementary Fig. 1A). The optimal
cut-off to discriminate grade 2 from grade 3 proteinuria by UPCR
was 2.43 (96.9% sensitivity; 82.5% specificity) (Supplementary
Fig. 1B), the positive likelihood ratio was 5.54, and the negative
likelihood ratio was 0.038. For ease of clinical use, a cut-off of 2.4 is
proposed.
Correlation between 24-hour urine protein collection and UPCR
After removal of a single outlier from the regression model,
regression analysis of UPCR versus 24-hour urine protein collection
data showed a statistically significant correlation, with a Pearson
correlation coefficient (R) of 0.86, an R2 of 0.75, and slope of
0.9 (P < 2 × 10−16) (Fig. 1a). Below the grade 3 optimal UPCR cut-
off level (2.4), only 1 test out of 239 had grade 3 proteinuria based
on 24-hour urine collection but not based on UPCR (Fig. 1a). Using
the grade 1+ 2 versus grade 3 proteinuria UPCR cut-off of 2.4 as
an optimal cut-off to determine which patients should undergo
further testing with 24-hour urine collection, 239/323 pairs of tests
were below or equal to this cut-off and only 1 test was missed
(0.4%); thus, the need for 24-hour urine collection would be
reduced by 74% (Fig. 1b). Also, 84/323 (26%) pairs of tests were
above this cut-off, with 53/84 (63%) pairs being grade 1+ 2
proteinuria.
DISCUSSION
The mechanism underlying VEGFR-inhibitor-associated proteinuria
are unclear, but may involve thrombotic microangiopathy or
impairment of podocyte function.14 However, proteinuria is a
manageable adverse event that does not typically lead to clinically
meaningful adverse outcomes if it is appropriately monitored and
managed.3,14 The regression model of the UPCR versus 24-hour
urine protein data suggests a strong and statistically significant
correlation between the 2 measurements, and using a UPCR cut-
off value of 2.4 to delineate between grade 2 and 3 proteinuria
and the need for further testing would obviate the need for the
more burdensome 24-hour urine collection for an estimated 74%
of patients with urine protein dipstick results of ≥2+.
Introduction of UPCR into the guidelines for proteinuria
management could be as follows and as described in Supple-
mentary Table 2: urine dipstick testing would be performed as
regularly scheduled. A 24-hour urine collection or an immediate
spot UPCR test would be required in the case of: (1) first
occurrence of ≥2+ proteinuria while on lenvatinib; (2) a
subsequent increase in severity of urine dipstick proteinuria while
on the same dose level; (3) when following a lenvatinib dose
reduction, the urine protein dipstick result was ≥2+. In addition, a
24-hour urine collection should be initiated as soon as possible
(within 72 h) when UPCR is ≥2.4 to verify the grade of proteinuria.
After the proteinuria has improved to a lower grade, lenvatinib
may be restarted at a reduced dose. By following these criteria,
proteinuria can be safely managed, enabling optimisation of
lenvatinib treatment while minimising inconvenience to patients.
It should also be noted that, although this analysis was conducted
in patients with HCC, this monitoring approach may potentially be
useful in other tumour types treated with lenvatinib (e.g.
differentiated thyroid cancer or renal cell carcinoma).
CONCLUSIONS
Data from this large study support the use of UPCR for proteinuria
monitoring in patients with unresectable HCC who are receiving
lenvatinib therapy and have ≥2+ urine protein during routine
monitoring, similar to its use in other diseases. Use of this test
would alleviate the need for 24-hour urine collection in most
cases, therefore reducing patient burden.
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Fig. 1 a Correlation between 24-hour urine protein collection and
UPCR, analysed using a regression model of log-transformed data
(323 paired tests). The red arrow indicates a single test that had
grade 3 proteinuria based on 24-hour urine collection but not with
UPCR based on the optimal UPCR cut-off value of 2.4; b proposed
UPCR cut-off values for determining whether to perform 24-hour
urine collection. Units of measurement are mg/dl for urine protein,
and ratio for UPCR. Ln, natural log; UPCR, urine protein:
creatinine ratio
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